Drug General Information
Drug ID	D0Q4AQ
Former ID	DNC010250
Drug Name	6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[530516]
Structure		Download 2D MOL 3D MOL
Formula	C10H12BrN5
Canonical SMILES	C1CN(CCN1)C2=NC(=CN3C2=NC=C3)Br
InChI	1S/C10H12BrN5/c11-8-7-16-6-3-13-9(16)10(14-8)15-4-1-12-2-5-15/h3,6-7,12H,1-2,4-5H2
InChIKey	XNILOZDQMHSDIZ-UHFFFAOYSA-N
PubChem Compound ID	46228424
Target and Pathway
Target(s)	5-hydroxytryptamine 2C receptor	Target Info	Inhibitor	[530516]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Gap junction
	Serotonergic synapse
	Inflammatory mediator regulation of TRP channels
PANTHER Pathway	5HT2 type receptor mediated signaling pathway
Reactome	Serotonin receptors
	G alpha (q) signalling events
WikiPathways	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 530516	Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 530516	Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.